WallStSmart
APVO

Aptevo Therapeutics Inc

NASDAQ: APVO · HEALTHCARE · BIOTECHNOLOGY

$4.81
-1.94% today

Updated 2026-04-29

Market cap
$5.68M
P/E ratio
P/S ratio
2.70x
EPS (TTM)
$-87.27
Dividend yield
52W range
$4 – $189
Volume
0.1M

Aptevo Therapeutics Inc (APVO) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
+42.2%
Last 4 quarters
Revenue YoY growth
Most recent quarter
EPS YoY growth
+96.7%
Most recent quarter

When is the next earnings report?

Reporting date
December 31, 2025
Consensus EPS estimate
$-8.09
Fiscal period ending
2025-12-31

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+0.2%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
+2.8%
2025-11-06
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-04-01$-5.91$4.27$4.17-2.3%
2025-11-06$-2.23+41.0%$1.43$1.47+2.8%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2026-03-31$-5.91
2025-12-31$-8.09$-220000.00
2025-09-30$-3.78$-2.23+41.0%
2025-06-30$-83.20$-8.40+89.9%
2025-03-31$-84.20$-87.80-4.3%
2024-12-31$-155.00$-178.80-15.4%
2024-09-30$-421.80$-355.20+15.8%
2024-06-30$-6.55$-1.67+74.5%
2024-03-31$-12.84$-9.95+22.5%
2023-12-31$-18.04$-6.16+65.9%$902000.00
2023-09-30$-0.75$-0.50+33.3%

Frequently asked questions

When does Aptevo Therapeutics Inc report next earnings?
Aptevo Therapeutics Inc (APVO) is scheduled to report earnings on December 31, 2025. The consensus EPS estimate is $-8.09.
Has Aptevo Therapeutics Inc beaten earnings estimates?
Aptevo Therapeutics Inc has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of +42.2% over the last 3 quarters.
How does APVO stock react to earnings?
APVO stock has moved an average of +0.2% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.